Alemtuzumab Clearance, Lymphocyte Count, and T‐Cell Chimerism After Hematopoietic Stem Cell Transplant in Sickle Cell Disease

2021 ◽  
Author(s):  
Dana Furstenau ◽  
Cody J. Peer ◽  
Thomas E. Hughes ◽  
Naoya Uchida ◽  
John Tisdale ◽  
...  
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
Sickle Cell Disease ◽  
Hematopoietic Stem Cell ◽  
Lymphocyte Count ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Cell Disease ◽  
Hematopoietic Stem

Allogeneic hematopoietic stem cell transplant for sickle cell disease: The why, who, and what

Blood Reviews ◽  
2021 ◽  
pp. 100868
Author(s):  
Emanuela Cimpeanu ◽  
Maria Poplawska ◽  
Brian Campbell Jimenez ◽  
Dibyendu Dutta ◽  
Seah H. Lim
Keyword(s):  
Stem Cell ◽  
Sickle Cell Disease ◽  
Hematopoietic Stem Cell ◽  
Sickle Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Cell Disease ◽  
Hematopoietic Stem

The ethics of a proposed study of hematopoietic stem cell transplant for children with “less severe” sickle cell disease

Blood ◽  
2014 ◽  
Vol 124 (6) ◽  
pp. 861-866 ◽  
Author(s):  
Robert S. Nickel ◽  
Jeanne E. Hendrickson ◽  
Ann E. Haight
Keyword(s):  
Stem Cell ◽  
Sickle Cell Disease ◽  
Hematopoietic Stem Cell ◽  
Sickle Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Individual Autonomy ◽  
Cell Transplant ◽  
Cell Disease ◽  
Hematopoietic Stem

Abstract Hematopoietic stem cell transplant (HSCT) is the only cure for sickle cell disease (SCD). HSCT using an HLA-identical sibling donor is currently an acceptable treatment option for children with severe SCD, with expected HSCT survival >95% and event-free survival >85%. HSCT for children with less severe SCD (children who have not yet suffered overt disease complications or only had mild problems) is controversial. It is important to consider the ethical issues of a proposed study comparing HLA-identical sibling HSCT to best supportive care for children with less severe SCD. In evaluating the principles of nonmaleficence, respect for individual autonomy, and justice, we conclude that a study of HLA-identical sibling HSCT for all children with SCD, particularly hemoglobin SS and Sβ0-thalassemia disease, is ethically sound. Future work should explore the implementation of a large trial to help determine whether HSCT is a beneficial treatment of children with less severe SCD.

Improved Splenic Function After Hematopoietic Stem Cell Transplant for Sickle Cell Disease

2016 ◽  
Vol 63 (5) ◽  
pp. 908-913 ◽  
Author(s):  
Robert Sheppard Nickel ◽  
Elizabeth Seashore ◽  
Peter A. Lane ◽  
Adina L Alazraki ◽  
John T. Horan ◽  
...  
Keyword(s):  
Stem Cell ◽  
Sickle Cell Disease ◽  
Hematopoietic Stem Cell ◽  
Sickle Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Cell Disease ◽  
Hematopoietic Stem ◽  
Splenic Function
Sign in / Sign up

Export Citation Format

Share Document